Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516241 · ClinicalTrials.gov registry record · Phase 3
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
A Phase 3 study of Urothelial Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,126
- Enrollment target
- 20
- Study locations
NCT02516241 is a Phase 3 study of Urothelial Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,126 participants, above the 529-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (113% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT02516241, a Phase 3 study of Urothelial Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,126 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Tremelimumab
- DRUG MEDI4736 (Durvalumab)
Study Locations (20)
Other
- Research Site - Box Hill
- Research Site - Elizabeth Vale
- Research Site - Macquarie University
- Research Site - St Leonards
California
- Research Site - Los Angeles
- Research Site - Stanford
Michigan
- Research Site - Ann Arbor
- Research Site - Detroit
New York
- Research Site - New York
- Research Site - New York
Tennessee
- Research Site - Memphis
- Research Site - Nashville
Colorado
- Research Site - Aurora
Connecticut
- Research Site - New Haven
Florida
- Research Site - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,126 participants |
| Start Date | 2015-11-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516241
The ClinicalTrials.gov registry entry for NCT02516241 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,126 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 529-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (113% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT02516241 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT02516241 about?
NCT02516241 is a clinical study titled "Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer". A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
What is the current status of trial NCT02516241?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,126 participants. The study started on 2015-11-02. Estimated completion is 2026-12-31.
What conditions does trial NCT02516241 study?
This clinical trial studies the following conditions: Urothelial Cancer.
What interventions are being tested in trial NCT02516241?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Tremelimumab (DRUG), MEDI4736 (Durvalumab) (DRUG).
Who is sponsoring clinical trial NCT02516241?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02516241 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
ACTIVE NOT RECRUITING · Phase 3
-
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ACTIVE NOT RECRUITING · Phase 3
-
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
COMPLETED · Phase 3
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.